Premium
Prognostic factors for therapeutic outcome of diffuse small non‐cleaved cell lymphoma in adults
Author(s) -
Morrison Vicki A.,
Frizzera Glauco,
Arthur Diane C.,
Ogle Kathleen M.,
Hurd David D.,
Bloomfield Clara D.,
Peterson Bruce A.
Publication year - 1994
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830460408
Subject(s) - medicine , vincristine , cyclophosphamide , prednisone , gastroenterology , methotrexate , lymphoma , stage (stratigraphy) , chemotherapy , regimen , population , b symptoms , surgery , paleontology , environmental health , biology
Most reports of prognosis and therapy in diffuse small non‐cleaved cell lymphoma (DSNCL), an aggressive high‐grade non‐Hodgkin's lymphoma (NHL) which appears to be of two histopathologic subtypes, have included predominantly a pediatric population and very few adults. We studied 20 newly diagnosed, previously untreated adults with DSNCL. Three patients had Ann Arbor Stage I disease, five Stage II, and 12 Stage IV. Bone marrow involvement was present in seven of 20 (35%) patients; no patient had central nervous system involvement at diagnosis. Clonal chromosomal abnormalities were found on cytogenetic analysis of all 12 cases studied. Ten patients had specific recurring translocations, including t(8;14) (q23;q32) (five patients), t(14;18) (q32;q21) (four patients), and t(2;8) (p12;q24) (one patient). Induction chemotherapy with the COMP regimen (cyclophosphamide, vincristine, methotrexate, and prednisone) or a variant schedule of the same drugs resulted in complete remission for 13 patients (65%), and partial remission for 5 patients (25%). Clinical characteristics predictive of a favorable response to induction therapy included Stage I or II disease, a normal lactic dehydrogenase (LDH), and performance status (PS) of 0 or 1. Remission duration ranged from two to 125+ (median 37+) months. Survival ranged from one to 126+ (median 23) months; ten patients (50%) remain alive, nine with no active disease. Factors predictive of longer survival included achievement of a complete remission with induction therapy, a normal LDH, and PS 0 or 1. As in children with DSNCL, long‐term disease‐free survival may be achieved in adults with combination chemotherapy. © 1994 Wiley‐Liss, Inc.